📊 AZTR Key Takeaways
Is Azitra, Inc. (AZTR) a Good Investment?
Azitra is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial position. The company is consuming $11.2M in annual operating cash flow with only $2.1M in cash reserves, creating an acute liquidity crisis within months. Negative profitability, zero revenue generation, and massive operating losses indicate the company is not executing on its business model.
Azitra remains a pre-revenue biotechnology company with no commercial sales, persistent operating losses, and deeply negative cash generation, indicating that the business has not yet demonstrated economic viability. While the balance sheet is not heavily levered and liquidity is still above 1x, the cash balance of $2.07M appears thin relative to annual operating cash burn of $11.22M, implying substantial financing risk unless fundamentals improve materially.
Why Buy Azitra, Inc. Stock? AZTR Key Strengths
- Current ratio of 2.83x provides short-term liquidity cushion
- Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk
- Recent insider activity suggests management engagement with business
- Debt-free capital structure reduces financial leverage risk
- Current and quick ratios of 2.83x indicate near-term balance sheet liquidity is still adequate
- Net loss improved year over year, suggesting some operating cost progress
AZTR Stock Risks: Azitra, Inc. Investment Risks
- Zero revenue with -$11.0M net loss indicates complete commercial failure or pre-commercial stage misrepresentation
- Operating cash burn of -$11.2M annually against $2.1M cash reserves means runway exhausted within 2-3 months
- Negative ROE of -288.2% and ROA of -218.0% demonstrate severe value destruction
- Stockholders' equity of $3.8M being depleted rapidly, risking equity dilution or insolvency
- No visible path to profitability with pharmaceutical development cycle requirements
- Zero revenue means the company has not yet proven product commercialization or recurring demand
- Operating cash flow of -$11.22M versus only $2.07M in cash suggests limited runway and likely dependence on external funding
- Returns on equity and assets are extremely negative, reflecting weak capital efficiency and ongoing value erosion
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue recognition milestone or clinical trial progression
- Equity dilution and financing activities
- Operating cash flow trajectory and burn rate stabilization
- Quarterly cash burn relative to cash on hand
- Evidence of revenue generation from commercialization, licensing, or collaboration agreements
Azitra, Inc. (AZTR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.83x current ratio provides a solid financial cushion.
AZTR Profit Margin, ROE & Profitability Analysis
AZTR vs Healthcare Sector: How Azitra, Inc. Compares
How Azitra, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Azitra, Inc. Stock Overvalued? AZTR Valuation Analysis 2026
Based on fundamental analysis, Azitra, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Azitra, Inc. Balance Sheet: AZTR Debt, Cash & Liquidity
AZTR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Azitra, Inc.'s revenue has declined by 99% over the 5-year period, indicating business contraction. The most recent EPS of $-15.70 indicates the company is currently unprofitable.
AZTR Revenue Growth, EPS Growth & YoY Performance
AZTR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$1.0M | $-0.67 |
| Q2 2025 | N/A | -$2.6M | $-0.18 |
| Q3 2024 | N/A | -$1.0M | $-0.17 |
| Q2 2024 | $7.5K | -$2.5M | $-2.74 |
| Q1 2024 | N/A | -$2.5M | $-0.15 |
| Q3 2023 | $48.5K | -$1.9M | $-0.16 |
| Q2 2023 | $85.0K | -$1.9M | $-2.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Azitra, Inc. Dividends, Buybacks & Capital Allocation
AZTR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Azitra, Inc. (CIK: 0001701478)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AZTR
What is the AI rating for AZTR?
Azitra, Inc. (AZTR) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AZTR's key strengths?
Claude: Current ratio of 2.83x provides short-term liquidity cushion. Minimal debt burden with 0.00x debt-to-equity ratio reduces financial leverage risk. ChatGPT: Debt-free capital structure reduces financial leverage risk. Current and quick ratios of 2.83x indicate near-term balance sheet liquidity is still adequate.
What are the risks of investing in AZTR?
Claude: Zero revenue with -$11.0M net loss indicates complete commercial failure or pre-commercial stage misrepresentation. Operating cash burn of -$11.2M annually against $2.1M cash reserves means runway exhausted within 2-3 months. ChatGPT: Zero revenue means the company has not yet proven product commercialization or recurring demand. Operating cash flow of -$11.22M versus only $2.07M in cash suggests limited runway and likely dependence on external funding.
What is AZTR's revenue and growth?
Azitra, Inc. reported revenue of $0.0.
Does AZTR pay dividends?
Azitra, Inc. does not currently pay dividends.
Where can I find AZTR SEC filings?
Official SEC filings for Azitra, Inc. (CIK: 0001701478) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AZTR's EPS?
Azitra, Inc. has a diluted EPS of $-2.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AZTR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Azitra, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AZTR stock overvalued or undervalued?
Valuation metrics for AZTR: ROE of -288.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AZTR stock in 2026?
Our dual AI analysis gives Azitra, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AZTR's free cash flow?
Azitra, Inc.'s operating cash flow is $-11.2M, with capital expenditures of $24.2K.
How does AZTR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -288.2% (avg: 15%), current ratio 2.83 (avg: 2).